InflaRx (NASDAQ:IFRX) has earned a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $10.21.
Several equities research analysts recently weighed in on IFRX shares. Ci Capital reaffirmed a “hold” rating and issued a $7.00 price objective on shares of InflaRx in a report on Monday, September 14th. SVB Leerink upgraded shares of InflaRx from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $7.00 to $10.00 in a research report on Friday, November 6th. Lifesci Capital reiterated a “market perform” rating on shares of InflaRx in a research report on Friday, October 30th. HC Wainwright began coverage on shares of InflaRx in a research report on Thursday, October 8th. They issued a “buy” rating and a $11.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of InflaRx from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research report on Wednesday.
IFRX stock opened at $5.03 on Friday. The company has a market capitalization of $132.14 million, a P/E ratio of -3.07 and a beta of 0.52. The company has a 50-day simple moving average of $4.51 and a 200 day simple moving average of $4.62. InflaRx has a fifty-two week low of $2.52 and a fifty-two week high of $9.70.
InflaRx (NASDAQ:IFRX) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.07. On average, sell-side analysts expect that InflaRx will post -1.42 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of IFRX. Engineers Gate Manager LP acquired a new stake in InflaRx during the 2nd quarter worth about $67,000. Bank of America Corp DE raised its holdings in InflaRx by 184.7% during the 2nd quarter. Bank of America Corp DE now owns 21,900 shares of the company’s stock worth $101,000 after buying an additional 14,209 shares during the period. Squarepoint Ops LLC acquired a new stake in InflaRx during the 3rd quarter worth about $145,000. Schonfeld Strategic Advisors LLC raised its holdings in InflaRx by 63.3% during the 2nd quarter. Schonfeld Strategic Advisors LLC now owns 35,240 shares of the company’s stock worth $162,000 after buying an additional 13,655 shares during the period. Finally, Verition Fund Management LLC acquired a new stake in InflaRx during the 2nd quarter worth about $436,000. Hedge funds and other institutional investors own 13.73% of the company’s stock.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases.
Read More: Stock Market – What is a circuit breaker?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]